Durvalumab Biosimilar - Research Grade

Human

PD-L1

>1mg/ml

Human IgG1

Humanized

Anti-Mouse PD-L1 (10F.9G2) In Vivo Antibody - Low Endotoxin (ICH1086), Mouse Anti-Mouse PD-L1 (10F.9G2) Recombinant Antibody (ICH1183), Anti-Human PD-L1 (29E.2A3) In Vivo Antibody - Low Endotoxin (ICH1221), Avelumab Biosimilar - Research Grade (ICH4017), Atezolizumab Biosimilar - Research Grade (ICH4018), Envafolimab Biosimilar - Research Grade (ICH5177), Benmelstobart Biosimilar - Research Grade (ICH5388), Betifisolimab Biosimilar - Research Grade (ICH5397), Cemavafusp Biosimilar - Research Grade (ICH5431), Cosibelimab Biosimilar - Research Grade (ICH5451), Danburstotug Biosimilar - Research Grade (ICH5464), Garivulimab Biosimilar - Research Grade (ICH5565), Lesabelimab Biosimilar - Research Grade (ICH5635), Manelimab Biosimilar - Research Grade (ICH5667), Opucolimab Biosimilar - Research Grade (ICH5740), Pacmilimab Biosimilar - Research Grade (ICH5752), Socazolimab Biosimilar - Research Grade (ICH5870), Sudubrilimab Biosimilar - Research Grade (ICH5885), Tagitanlimab Biosimilar - Research Grade (ICH5895)

https://www.imgt.org/mAb-DB/

ICH3002

Q9NZQ7

29126

RRID:AB_2921556

Blue ice

ICH5005 is an unconjugated, non-therapeutic recombinant analog of durvalumab, a fully human IgG1 monoclonal antibody directed against human PD-L1 (CD274; UniProt Q9NZQ7). It is supplied for research use only and is not the clinical drug, nor is it intended for human or veterinary use. Built around the PD-L1 target, this biosimilar reproduces the antigen-binding specificity of the originator, making it a convenient reference tool for studying PD-1/PD-L1 axis blockade in vitro and in preclinical models. Typical research applications include use as a benchmarking or reference standard in binding and neutralization assays, as an isotype-matched or positive control alongside other checkpoint reagents, and as a starting scaffold for ADC or engineering workflows. Material is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options) and in bulk milligram-to-gram quantities to support assay development, screening, and in-vivo-grade preclinical formulation work. All content here is guidance for ichorbio to review and is not clinical documentation. PD-L1 (programmed death-ligand 1, also called CD274 or B7-H1) is a type I transmembrane glycoprotein of the B7 immunoglobulin superfamily. It is expressed on antigen-presenting cells, many normal tissues under inflammatory conditions, and is frequently upregulated on tumor cells. PD-L1 engages its principal receptor PD-1 (PDCD1) on activated T cells, delivering an inhibitory signal that dampens T-cell proliferation, cytokine production, and cytotoxic activity, thereby maintaining peripheral tolerance and limiting immunopathology. PD-L1 also binds CD80 (B7-1). Tumors exploit this pathway to evade immune surveillance, so antibodies that block PD-L1 restore effector T-cell function. Durvalumab binds PD-L1 and prevents its interaction with PD-1 and CD80, releasing this checkpoint brake.

Programmed cell death 1 ligand 1, Cd274, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, PDL-1

Detects human PDL-1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Durvalumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

SIM0027

Durvalumab (anti-PD-L1) Biosimilar

Q: Is the Durvalumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Durvalumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Durvalumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Durvalumab that binds human PD-L1.